A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed/Refractory Neuroblastoma
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2018
At a glance
- Drugs Dinutuximab (Primary) ; Iobenguane (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 06 Sep 2018 Status changed from not yet recruiting to recruiting.
- 01 Aug 2018 Planned End Date changed from 1 Dec 2021 to 1 Mar 2022.
- 01 Aug 2018 Planned primary completion date changed from 1 May 2021 to 1 Sep 2021.